Cannabis - Aspectos regulatorios: Políticas y regulación

Políticas de cannabis: regulación y aspectos económicos

• Fuente: PubMed [Internet]. Bethesda (MD): US National Library of Medicine National Institutes of Health; [consulta 25 mayo 2022]. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/
• Detalles de búsqueda: ((("cannabis"[MeSH Terms] OR "cannabis"[All Fields]) AND ("legal"[All Fields] OR "legalism"[All Fields] OR "legalities"[All Fields] OR "legality"[All Fields] OR "legalization"[All Fields] OR "legalize"[All Fields] OR "legalized"[All Fields] OR "legalizes"[All Fields] OR "legalizing"[All Fields] OR "legally"[All Fields]) AND ("Cost-Benefit Analysis"[MeSH Terms] OR ("economics"[MeSH Subheading] OR "economics"[All Fields] OR "economics"[MeSH Terms]))) NOT "drug policy"[All Fields]) AND (y_5[Filter])

 

2022

• Pereira-Morales AJ, Eslava-Schmalbach JH. Do alcohol and cannabis substitute or complement each other? Analysis from behavioral economics for formulating public policy on substance use in Colombia. Transl Behav Med. 24 de mayo de 2022;ibac038.
• Reed DD, Strickland JC, Gelino BW, Hursh SR, Jarmolowicz DP, Kaplan BA, et al. Applied behavioral economics and public health policies: Historical precedence and translational promise. Behav Processes. mayo de 2022;198:104640.
• El-Khoury J, Bou Khalil R, Nemer A, Richa S. Legalizing Medical Cannabis in Lebanon: the Complex Interface Between Medicine, Law, Ethics, and Economics. Cannabis Cannabinoid Res. abril de 2022;7(2):119-21.
• Wang GS, Buttorff C, Wilks A, Schwam D, Tung GJ, Banerji S, et al. Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. Am J Emerg Med. marzo de 2022;53:150-3.
• Wadsworth E, Driezen P, Pacula RL, Hammond D. Cannabis flower prices and transitions to legal sources after legalization in Canada, 2019-2020. Drug Alcohol Depend. 1 de febrero de 2022;231:109262.

2021

• Howard J, Wurzelbacher S, Osborne J, Wolf J, Ruser J, Chadarevian R. Review of cannabis reimbursement by workers’ compensation insurance in the U.S. and Canada. Am J Ind Med. diciembre de 2021;64(12):989-1001.
• Ferguson E, Bush N, Yurasek A, Boissoneault J. The effect of next day responsibilities and an adaptive purchase task on cannabis demand. Drug Alcohol Depend. 1 de octubre de 2021;227:108919.
• Erku D, Shrestha S, Scuffham P. Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations. Value Health. octubre de 2021;24(10):1520-30.
• Chiu V, Leung J, Hall W, Stjepanović D, Degenhardt L. Public health impacts to date of the legalisation of medical and recreational cannabis use in the USA. Neuropharmacology. 1 de agosto de 2021;193:108610.
• Armstrong MJ. Legal cannabis market shares during Canada’s first year of recreational legalisation. Int J Drug Policy. febrero de 2021;88:103028.
• Davenport S. Price and product variation in Washington’s recreational cannabis market. Int J Drug Policy. mayo de 2021;91:102547.

2020

• Hall W. The costs and benefits of cannabis control policies. Dialogues Clin Neurosci. septiembre de 2020;22(3):281-7.

2019

• Sheridan Rains L, Marston L, Hinton M, Marwaha S, Craig T, Fowler D, et al. Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial. BMC Med. 15 de agosto de 2019;17(1):161.
• Tyree GA, Sarkar R, Bellows BK, Ellis RJ, Atkinson JH, Marcotte TD, et al. A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. Cannabis Cannabinoid Res. 2019;4(1):62-72.
• Zimmermann K, Kendrick KM, Scheele D, Dau W, Banger M, Maier W, et al. Altered striatal reward processing in abstinent dependent cannabis users: Social context matters. Eur Neuropsychopharmacol. 2019;29(3):356-64 .
• McCoy MS. Addressing the Conflicts of Interest of Public Officials and Employees: Lessons From Cannabis Legalization. Am J Public Health. marzo de 2019;109(3):350-1.
• Amlung M, Reed DD, Morris V, Aston ER, Metrik J, MacKillop J. Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis. Addiction. enero de 2019;114(1):112-8.
• Amlung M, MacKillop J. Availability of legalized cannabis reduces demand for illegal cannabis among Canadian cannabis users: evidence from a behavioural economic substitution paradigm. Can J Public Health. abril de 2019;110(2):216-21.

2018

• Caldicott D, Sinclair J, Sheridan L, Eckermann S. Medicinal Cannabis and the Tyranny of Distance: Policy Reform Required for Optimizing Patient and Health System Net Benefit in Australia. Appl Health Econ Health Policy. abril de 2018;16(2):153-6.
• Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, et al. Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. Pharmacoeconomics. enero de 2018;36(1):67-78.
• Steinemann S, Galanis D, Nguyen T, Biffl W. Motor vehicle crash fatalaties and undercompensated care associated with legalization of marijuana. J Trauma Acute Care Surg. 2018;85(3):566-71.
• Hill KP, Saxon AJ. The Role of Cannabis Legalization in the Opioid Crisis. JAMA Intern Med. 01 de 2018;178(5):679-80.
• Chu Y-WL. Commentary on Sarvet et al. (2018): What do we still need to know about the impacts of medical marijuana laws in the United States? Addiction. junio de 2018;113(6):1017-8.
• Caulkins JP, Bao Y, Davenport S, Fahli I, Guo Y, Kinnard K, et al. Big data on a big new market: Insights from Washington State’s legal cannabis market. Int J Drug Policy. 2018;57:86-94.
• Belackova V, Wilkins C. Consumer agency in cannabis supply - Exploring auto-regulatory documents of the cannabis social clubs in Spain. Int J Drug Policy. 2018;54:26-34.

2017

• Vincent PC, Collins RL, Liu L, Yu J, De Leo JA, Earleywine M. The effects of perceived quality on behavioral economic demand for marijuana: A web-based experiment. Drug Alcohol Depend. 1 de enero de 2017;170:174-80.
• van Ours JC. Data on cannabis use now that legalization is gaining momentum. Addiction. 2017;112(7):1138-40.
• Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction. diciembre de 2017;112(12):2167-77.
• McGinty EE, Niederdeppe J, Heley K, Barry CL. Public perceptions of arguments supporting and opposing recreational marijuana legalization. Prev Med. junio de 2017;99:80-6.
• Hunt P, Pacula RL. Early Impacts of Marijuana Legalization: An Evaluation of Prices in Colorado and Washington. J Prim Prev. junio de 2017;38(3):221-48.
• Cronce JM, Bittinger JN, Di Lodovico CM, Liu J. Independent Versus Co-occurring Substance Use in Relation to Gambling Outcomes in Older Adolescents and Young Adults. J Adolesc Health. mayo de 2017;60(5):528-33.
• Carlini BH. Potency increase, product development and marijuana marketing in times of legalization. Addiction. diciembre de 2017;112(12):2178-9 .
• Carliner H, Mauro PM, Brown QL, Shmulewitz D, Rahim-Juwel R, Sarvet AL, et al. The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002-2014. Drug Alcohol Depend. 1 de enero de 2017;170:51-8.
• Álvarez A, Gamella JF, Parra I. The legalization of cannabis derivatives in Spain: Hypothesis on a potential emerging market. Adicciones. 28 de junio de 2017;29(3):195-206.

2016

• Williams J, van Ours JC, Grossman M. Attitudes to legalizing cannabis use. Health Econ. 2016;25(9):1201-16 .
• Pinkas J, Jabłoński P, Kidawa M, Wierzba W. Use of marijuana for medical purposes. Ann Agric Environ Med. septiembre de 2016;23(3):525-8.
• Kalant H. A critique of cannabis legalization proposals in Canada. Int J Drug Policy. 2016;34:5-10.
• Jensen EL, Roussell A. Field observations of the developing legal recreational cannabis economy in Washington State. Int J Drug Policy. 2016;33:96-101.
• Hajizadeh M. Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts. Int J Health Policy Manag. 25 de mayo de 2016;5(8):453-6 .
• Collier R. How will pot legalization affect medical marijuana? CMAJ. 9 de agosto de 2016;188(11):792-3.

2015

• Ogrodnik M, Kopp P, Bongaerts X, Tecco JM. An economic analysis of different cannabis decriminalization scenarios. Psychiatr Danub. septiembre de 2015;27 Suppl 1:S309-314.